预约演示
Caring Cross, Brazil's Fiocruz team up to produce cell and gene therapies at a fraction of their cost in the US
疫苗基因疗法细胞疗法
Maryland non-profit Caring Cross and Brazil's Fundacao Oswaldo Cruz (Fiocruz) plan to develop and manufacture cell and gene therapies at one-tenth of their cost in the U.S.
Maryland non-profit Caring Cross has unveiled a partnership with the Brazilian government that's designed to provide access to advanced cell and gene therapies for diseases like leukemia, lymphoma and HIV infection—and in the process provide a manufacturing model that demonstrates how to reduce the cost of these treatments in the United States and Europe.
Caring Cross and FunCaring Crosso Cruz (Fiocruz)—a foundation funded by the Brazilian Ministry of Health—plan to develop and manufacture the medicines at a fraction of their costleukemiaU.lymphomaHIV infection
Caring Crossy cell and gene therapy manufacturing trailblazers Boro DropulicBrazilian Ministry of Healtharing Cross’ mission is to organize and support a community of healthcare professionals, scientists, engineers, advocates and business leaders to accelerate the development of advanced medicines and make them available for all patients around the world.
The program with Brazil is the first of its kind anywhere in the world, Dropulic and Orentas said in an interview with Fierce Pharma.
“We’re pioneering something quite new in terms of teaching an organization, that is directly linked to the Ministry of Health, how to manufacture CAR-T cells and the vectors themselves,” said Dropulic, the executive director of Caring Cross. “We will start first in Rio de Janeiro at the Fiocruz campus—in collaboration with INCA, which is their equivalent of the NCI (National Cancer Institute)—to run clinical trials for leukemia and lymphoma.”
Dropulic knows the drill. He founded Lentigen, which developed the lentiviral vector used by Novartis to prMinistry of HealthA-approved cell therapy product, Kymriah, in 2017. Dropulic directed Lentigen’s CDMO business model before launching Caring Cross in 2021.INCANCINational Cancer InstituteCancerleukemialymphoma
Under the plan, the therapies will be available for free for patients, with an approximate cost of $35,000 per dose covered by the Brazilian psickle cell disease. Drobeta thalassemias believe an approved product could be available within three years.
Caring Cross aims to slash production costs with its point-of-care manufacturing model. Development and manufacturing can be executed entirely in modular units which are 56 by 13 feet and can be set up anywhere.
“When you make these products at the point of care or close to a hospital, you significantly decrease these logistical costs,” Dropulic said.
Orentas added that it’s already dawned on the managed care systems in countries such as Spain, Germany and Denmark that the way gene therapies are produced in the U.S. is “not sustainable.” Even with the high cost of doing business in the U.S., Caring Cross believes it could deliver CAR-T therapies for around $80,000, Orentas said.
In the U.S., cell and gene therapy prices currently range from hundreds of thousands of dollars to millions of dollars.Caring Cross
Caring Cross's Brazilian partner has "biomanufacturing expertise" and "an experienced workforce," Orentas said. Fiocruz is the world’s largest producer of the yellow fever vaccine. It also served as Brazil’s home base for production of its AstraZeneca-partnered COVID vaccine.
Caring Crosshrough its for-profit CDMO spinout, Vector BioMed, Caring Cross is developing technologies to improve the accessibility of CAR-T and other therapieyellow fever vaccineAstraZeneca
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。